- Home
- DTF vs ALRN Comparison
DTF vs ALRN Comparison
Compare DTF & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- ALRN
- Stock Information
- Founded
- DTF 1991
- ALRN 2001
- Country
- DTF United States
- ALRN United States
- Employees
- DTF N/A
- ALRN N/A
- Industry
- DTF Investment Managers
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- ALRN Health Care
- Exchange
- DTF Nasdaq
- ALRN Nasdaq
- Market Cap
- DTF 78.9M
- ALRN 76.9M
- IPO Year
- DTF N/A
- ALRN 2017
- Fundamental
- Price
- DTF $11.24
- ALRN $2.58
- Analyst Decision
- DTF
- ALRN Strong Buy
- Analyst Count
- DTF 0
- ALRN 1
- Target Price
- DTF N/A
- ALRN $19.00
- AVG Volume (30 Days)
- DTF 21.1K
- ALRN 87.4K
- Earning Date
- DTF 01-01-0001
- ALRN 11-14-2024
- Dividend Yield
- DTF 3.64%
- ALRN N/A
- EPS Growth
- DTF N/A
- ALRN N/A
- EPS
- DTF 0.44
- ALRN N/A
- Revenue
- DTF N/A
- ALRN N/A
- Revenue This Year
- DTF N/A
- ALRN N/A
- Revenue Next Year
- DTF N/A
- ALRN N/A
- P/E Ratio
- DTF $24.34
- ALRN N/A
- Revenue Growth
- DTF N/A
- ALRN N/A
- 52 Week Low
- DTF $10.29
- ALRN $1.61
- 52 Week High
- DTF $11.19
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- DTF 45.87
- ALRN 29.28
- Support Level
- DTF $11.21
- ALRN $2.67
- Resistance Level
- DTF $11.37
- ALRN $3.11
- Average True Range (ATR)
- DTF 0.07
- ALRN 0.38
- MACD
- DTF -0.00
- ALRN -0.15
- Stochastic Oscillator
- DTF 37.97
- ALRN 4.85
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTFTax-Free Income Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax consistent with preservation of capital. The fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.